Company: TELO
Filing Date: 2025-02-04
Form Type: 10-K
Source: 0001493152-25-004872
Chunk: 758

Company: Telomir Pharmaceuticals, Inc.
Filing Date: 2025-02-04
Form: 10-K
Item: Item 3
Chunk 758
---
 costs necessary to obtain regulatory approvals, if any, for any approved products in the United States and other jurisdictions, and
    the costs of post-marketing studies that could be required by regulatory authorities in jurisdictions where approval is obtained;

    ●
    the
    costs and timing of preparing, filing and prosecuting patent applications, maintaining and enforcing our intellectual property rights
    and defending any intellectual property-related claims;

    ●
    the
    continuation of our existing licensing arrangements and entry into new collaborations and licensing arrangements;

    ●
    the
    costs we incur in maintaining business operations;

    ●
    the
    costs of hiring additional clinical, quality control, manufacturing and other scientific personnel;

    ●
    the
    costs adding operational, financial and management information systems and personnel;

    ●
    the
    costs associated with being a public company;

    ●
    the
    revenue, if any, received from commercial sales of our programs for which we receive marketing approval;

    ●
    the
    effect of competing technological and market developments; and

    ●
    the
    extent to which we acquire or invest in businesses, products and technologies, including entering into licensing or collaboration
    arrangements for programs.

Identifying
potential programs, product candidates, conducting pre-clinical studies and clinical trials is a time consuming, expensive and uncertain
process that takes years to complete, and we may never generate the necessary data or results required to obtain marketing approval and
achieve product sales. In addition, our programs, if approved, may not achieve commercial success. Our commercial revenues, if any, will
be derived from sales of products that we do not expect to be commercially available for many years, if ever. Accordingly, we will need
to obtain substantial additional funds to achieve our business objectives.

Recently
Issued and Adopted Accounting Pronouncements

A
description of recently issued and adopted accounting pronouncements that may potentially impact our financial position and results of
operations is disclosed in Note 1 to our financial statements appearing at the end of this Annual Report.

Off-Balance
Sheet Arrangements

During
the periods presented, we did not have, nor do we currently have, any off-balance sheet arrangements as defined under Generally Accepted
Accounting Principles (GAAP) and SEC rules.

52

Summary
of Critical Accounting Policies and Estimates

Research
and development expenses

Research
and development costs are